Cipla Ltd.
NSE: CIPLACipla Ltd.: A 30-second snapshot
Cipla trades at Rs 1,463, up 3.12% over the trailing 3 months but down 0.96% over the trailing 1 year, sitting 11.73% below its 52-week high while holding above both the 50-DMA (Rs 1,426.93) and 200-DMA (Rs 1,391.53). Q1 FY27 net profit was reported down about 39% YoY on weaker North America sales, in line with 5-year earnings growth of -39.2%, even as the trailing PE of 35.10 compresses to a forward PE of 23.05.
P/E
35.1
Forward P/E
23.0
ROE
—
Debt / Equity
1.78
Profit Margin
+12.0%
Div. Yield
+0.9%
5Y ROE > 15%
2/5
5Y FCF > 0
4/5
Quality
51/100
News
8 headlines · 2 positive · 5 negative
Cipla Gets USFDA Inspection Closure for InvaGen Plant - HDFC Sky
HDFC Sky
India's Cipla posts another profit decline, names insider Dinesh Jain CFO - Reuters
Reuters
Cipla Q1 net profit drops 39% to Rs 785.55 crore, North America sales down - Rediff
Rediff
Indian drugmaker Cipla's quarterly profit shrinks more than expected - Yahoo Finance Singapore
Yahoo Finance Singapore
Cipla Q1 results: Profit falls 39% YoY to ₹789 crore; revenue climbs 3.50% - livemint.com
livemint.com
Recent context
- ·Reuters reported (July 23, 2026) 'another profit decline' as Cipla's Q1 net profit fell 39% YoY to about Rs 785.55 crore, with North America sales down.
- ·Cipla received USFDA inspection closure for its InvaGen plant, reported August 4, 2026 by HDFC Sky.
- ·Livemint reported (July 23, 2026) Q1 profit down 39% YoY to Rs 789 crore while revenue climbed 3.50% YoY.
Strengths
- +Debt-to-equity of roughly 0.02x (raw metric 1.78, percent-scaled) with a 'falling' debt trend per the persistence data and free cash flow positive in 4 of the last 5 tracked years.
- +Forward PE of 23.05 compares to a trailing PE of 35.10, a roughly 34% compression.
- +Mean analyst rating of 2.19 across 36 analysts (1-5 scale, lower = more constructive).
- +Price trades above both the 50-DMA (Rs 1,426.93) and 200-DMA (Rs 1,391.53), with RSI at a neutral 55.74, and trailing PE ranks 2nd-lowest among 6 tracked Pharma peers.
Weaknesses
- −5-year earnings growth of -39.2%, echoed in Q1 FY27 net profit reported down about 39% YoY to roughly Rs 785-789 crore on weaker North America sales.
- −ROE exceeded 15% in only 2 of the last 5 tracked years; profit margin stands at 12.01%.
- −Quality score of 28 ranks 5th of 6 tracked Pharma peers; 5-year revenue growth has been muted at 3.5%.
- −News sentiment across 8 tracked items skews negative (5 negative, 2 positive, 1 neutral), concentrated around the Q1 FY27 results.
Open questions
- ?Does the 39% YoY Q1 profit decline reflect a one-off North America sales headwind or a more structural margin pressure, given the -39.2% 5-year earnings growth trend?
- ?How does the falling debt trend and 4-of-5-year positive free cash flow history weigh against the 5th-of-6 quality-score ranking within the Pharma peer set?
- ?What would need to change for ROE to clear the 15% threshold more consistently, given it was achieved in only 2 of the last 5 years?
- ?Does the forward PE of 23.05 already price in an earnings recovery relative to the trailing PE of 35.10, or would that gap widen if the profit decline extends into Q2?
Peer comparison: Pharma
Ranks 5 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| CIPLA | Cipla Ltd.You're viewing | 35.1 | — | 28 |
| Industry avg | across 5 peers | 58.5 | +14.9% | 40 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 38.6 | — | 57 |
| DIVISLAB | Divi's Laboratories Ltd. | 88.3 | — | 57 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 65.0 | +21.5% | 44 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 70.5 | +14.3% | 37 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 30.3 | +8.8% | 4 |
Technical state
Current price
₹1,463.00
SMA 50
₹1,426.93
SMA 200
₹1,391.53
RSI (14)
55.7 (neutral)
From 52w high
-11.7%
1Y return
-1.0%
3M return
+3.1%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- high5-year earnings growth stands at -39.2%, matched by Q1 FY27 results (reported July 23, 2026) showing net profit down about 39% YoY to roughly Rs 785-789 crore on weaker North America sales; ROE exceeded 15% in only 2 of the last 5 tracked years.
- mediumQuality score of 28 ranks 5th of 6 tracked Pharma peers, and 5-year revenue growth has been muted at 3.5%, even though trailing PE of 35.10 ranks 2nd-lowest of the peer group.
- medium5 of 8 tracked news items are negative (2 positive, 1 neutral), overall label negative, with coverage concentrated on the Q1 FY27 results reported July 23, 2026 describing the profit decline and weaker North America sales.
- lowCurrent price of Rs 1,463 sits within about 0.25% of the nearest resistance level (Rs 1,466.6) after a 3.12% rally over the trailing 3 months; price is 11.73% below its 52-week high and down 0.96% over the trailing 1 year despite trading above both the 50-DMA (Rs 1,426.93) and 200-DMA (Rs 1,391.53).
Cross-section contradictions
- Forward PE of 23.05 is about 34% below trailing PE of 35.10, consistent with an expectation of earnings recovery, while 5-year earnings growth is -39.2% and Q1 FY27 net profit (reported July 23, 2026) was down about 39% YoY -- reported results have not yet shown the recovery implied by the forward multiple.
- Price trades above both the 50-DMA and 200-DMA with RSI at a neutral 55.74 and a mean analyst rating of 2.19 across 36 analysts (1-5 scale, lower = more constructive), while news sentiment across 8 tracked items skews negative (5 of 8) and the quality score ranks 5th of 6 Pharma peers.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 11 Aug 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 12 Aug 2026 · rotates through NIFTY 500 every ~5 days